title: Steve Carney talks to Mark Ashton and Mark Whittaker about Evotec and their approach to fragment-based drug discovery.
authors.affiliation: Evotec.
authors.forename: Mark
authors.initials: M
authors.lastname: Ashton
authors.forename: Mark
authors.initials: M
authors.lastname: Whittaker
mesh_terms: D001709:Biotechnology / Q000639:trends*; D002626:Chemistry, Pharmaceutical / Q000639:trends*; D015195:Drug Design; D004345:Drug Industry / Q000379:methods* / Q000639:trends; D009682:Magnetic Resonance Spectroscopy; D017149:Private Sector; D054852:Small Molecule Libraries; D013329:Structure-Activity Relationship
chemical_list: D054852:Small Molecule Libraries